Merck KGaA expands chemicals business with $17bn Sigma-Aldrich buy
This article was originally published in Scrip
Executive Summary
German pharmaceuticals and chemicals group Merck KGaA is to buy R&D chemicals maker Sigma-Aldrich for $140 per share in cash, valuing the US company at around $17bn. Despite the move, Merck chairman Karl-Ludwig Kley disputes any suggestion that Merck is deprioritizing pharmaceuticals.
You may also be interested in...
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.